国际皮肤性病学杂志    2006 32 (5): 279-281   ISSN: 2096-5540  CN: 32-1880/R   肿瘤坏死因子抑制剂治疗银屑病临床安全性评价 陈敏, 崔盘根, 陈志强 中国医学科学院、中国协和医科大学皮肤病研究所, 南京210042 收稿日期 2006-02-23  修回日期 null  网络版发布日期 null 参考文献  [1] Lee SJ,Yedla P,Kavanaugh A.Secondary immune deficiencies associated with biological therapeutics.Curr Allergy Asthma Rep,2003,3:389-395. [2] Mohan VP,Scanga CA,Yu K,et al.Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis:possible role for limiting pathology.Infect Immun,2001,69:1847-1855. [3] Bieber J,Kavanaugh A.Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.Rheum Dis Clin North Am,2004,30:257. [4] Symmons DP,Silman AJ.Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis:no clear answer.Arthritis Rheum,2004,50:1703-1706. [5] Magnano MD,Robinson WH,Genovese MC.Demyelination and inhibition of tumor necrosis factor (TNF).Clin Exp Rheumatol,2004,22(5 Suppl 35):S134-140. [6] Swale VJ,Perrett CM,Denton CP,et al.Etanercept-induced systemic lupus erythematosus.Clin Exp Dermatol,2003,28:604-607. [7] Mann DL,McMurray JJ,Packer M,et al.Targeted anticytokine therapy in patients with chronic heart failure:results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).Circulation,2004,109:1594-1602. [8] Wolfe F,Michaud K.Heart failure in rheumatoid arthritis:rates,predictors,and the effect of anti-tumor necrosis factor therapy.Am J Med,2004,116:305-311. [9] Mohan N,Edwards ET,Cupps TR,et al.Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.J Rheumatol,2004,31:1955-1958. [10] van Vollenhoven RF.Switching between biological agents.Clin Exp Rheumatol,2004,22(5 Suppl 35):S115-121. [11] Genovese MC,Cohen SB,Moreland L,et al.A randomized double-blind controlled trial study evaluating the safety and efficacy of etanercept vs etanercept plus anakinra in patients with rheumatoid arthritis.Ann Rheum Dis,2003,62(Suppl 1):66. [12] Schiff MH,Bulpitt K,Weaver AA,et al.Safety of combination therapy with anakinra and etanercept in patients with rheumatoid.arthritis.Arthritis Rheum,2001,44(Suppl 9):S79. [13] Antoni CE,Furst D,Manger B,et al.Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis.Arthritis Rheum,2001,44(suppl):S152. [14] Fleischmnn R,Iqbal I,Nandeshwar P,et al.Safety and efficacy of disease-modifying anti-rheumatic agents:focus on the benefits and risks of etanercept.Drug Saf,2002,25:173-197. [15] Abrams JR,Lebwohl MG,Guzzo CA,et al.CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.J Clin Invest,1999,103:1243-1252. [16] Naldi L,Griffiths CE.Traditional therapies in the management of moderate to severe chronic plaque psoriasis:an assessment of the benefits and risks.Br J Dermatol,2005,152:597-615. 通讯作者: